Test Price
800 AED✅ Home Collection Available
Sickle Cell Anemia Mutation Detection Test in UAE | 800 AED | 2026 DHA Guidelines
تحليل الكشف عن طفرة فقر الدم المنجلي في الإمارات | 800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي
يقدم هذا التحليل الجيني المتقدم كشفًا دقيقًا للطفرات المسببة لفقر الدم المنجلي باستخدام تقنية تفاعل البوليميراز المتسلسل وتسلسل الحمض النووي، وفقًا لأعلى معايير هيئة الصحة بدبي لعام 2026. نضمن دقة تشخيصية بنسبة 99.9% من خلال مختبرات معتمدة دوليًا بموجب شهادة ISO 9001:2015، مع خدمة سحب دم منزلي متميزة واستشارة طبية هاتفية بعد النتائج.
Comprehensive Clinical Overview
The Sickle Cell Anemia Mutation Detection Test is a definitive molecular diagnostic assay that identifies pathogenic variants in the HBB gene (beta-globin locus) responsible for sickle cell disease. This advanced genetic analysis employs polymerase chain reaction (PCR) amplification followed by Sanger DNA sequencing to detect the hallmark c.20A>T (p.Glu7Val) mutation, as well as compound heterozygous states including HbC, HbD-Punjab, HbO-Arab, and rare beta-thalassemia interactions that modulate clinical severity. For UAE patients, where consanguinity rates and hemoglobinopathy carrier frequencies remain significant public health priorities under the 2026 DHA National Genomics Strategy, this test delivers unambiguous genotype confirmation essential for prenatal counseling, premarital screening compliance, and personalized disease management planning.
يُعد هذا الفحص الجزيئي المتقدم الأداة التشخيصية المعتمدة لتحديد الطفرات المسببة لمرض فقر الدم المنجلي في جين HBB، مما يوفر تأكيدًا جينيًا دقيقًا ضروريًا للاستشارة الوراثية وإدارة المرض وفقًا لبروتوكولات هيئة الصحة بدبي.
| Feature | Our Sickle Cell Mutation Detection Test | Standard Hemoglobin Electrophoresis |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity; detects point mutations, compound heterozygosity, and silent carrier states at nucleotide resolution | Limited to protein-level detection; misses silent carriers and cannot distinguish HbS from rare co-migrating variants |
| Methodology | PCR Amplification + Sanger DNA Sequencing (Gold Standard), validated per ISO 9001:2015 | Alkaline and Acid Hemoglobin Electrophoresis; semi-quantitative |
| Turnaround Time | Sample Mon by 11 AM → Report Friday (5 business days) | Typically 3–7 business days; may require reflex to molecular testing for ambiguous results |
| Clinical Utility | Definitive genotype for prenatal diagnosis, premarital genetic counseling, and eligibility assessment for disease-modifying therapies | Screening only; requires molecular confirmation for diagnostic certainty |
Physician Insight & Safety Protocol
Clinical Correlation Note — Dr. Prabhakar Reddy, DHA License 61713011
As a clinician who has managed sickle cell disease across the UAE's diverse genetic landscape, I emphasize that a positive mutation detection result must always be interpreted alongside hemoglobin indices, reticulocyte counts, and clinical history. A negative result for the common HbS mutation does not exclude rare hemoglobinopathies, and any discordant clinical presentation warrants comprehensive globin gene sequencing. Your test report provides the molecular clarity needed, but the therapeutic decisions — from hydroxyurea initiation to transfusion protocols — must remain a shared decision between you and your hematologist.
Medication Advisory
Do not discontinue any prescribed medication — including hydroxyurea, L-glutamine, voxelotor, crizanlizumab, or opioid analgesics — without consulting your treating physician. Abrupt cessation may precipitate vaso-occlusive crisis, acute chest syndrome, or severe rebound pain episodes.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed with Home Collection If)
- Patient is currently experiencing acute vaso-occlusive crisis with severe pain (pain score ≥7/10)
- Active fever ≥38.5°C with clinical suspicion of acute chest syndrome or splenic sequestration
- Hemoglobin level below 5.0 g/dL on most recent assessment (within 72 hours)
- Patient has received packed red blood cell transfusion within the preceding 90 days (may confound molecular testing via donor DNA interference in peripheral blood)
- Current hospitalization in intensive care setting
Emergency Red Flags — Proceed Directly to Emergency Department
- Sudden onset dyspnea, tachypnea, or oxygen saturation below 92% on room air
- Acute neurological deficit: confusion, seizure, focal weakness, or visual disturbance
- Priapism lasting more than 4 hours (urological emergency)
- Severe pallor with lethargy and hemodynamic instability (suggestive of aplastic crisis or splenic sequestration)
- Temperature exceeding 39°C with rigors in a patient with sickle cell disease (presumptive sepsis until proven otherwise)
Specimen Collection & Transport Protocol
Sample Requirements
- Volume: 4 mL (minimum 2 mL) whole blood
- Collection Tube: 1 Lavender Top (EDTA) tube
- Transport Temperature: Ship refrigerated at 2–8°C
- Critical Instruction: DO NOT FREEZE — freezing causes leukocyte lysis and DNA degradation, rendering the sample unsuitable for PCR and sequencing
Pre-Test Documentation (Mandatory)
- Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory
- Include relevant clinical history: transfusion record (last 90 days), current medications, prior hemoglobin electrophoresis results if available
- Indicate clinical indication: diagnostic confirmation, carrier screening, prenatal counseling, or premarital assessment
Patient FAQ & Clinical Guidance
Q1: What does the Sickle Cell Anemia Mutation Detection Test actually diagnose, and how is it different from a routine hemoglobin electrophoresis test?
This molecular genetic test directly identifies the specific DNA mutation in the HBB gene that causes sickle cell anemia by analyzing the nucleotide sequence, providing definitive genotype confirmation that hemoglobin electrophoresis cannot achieve because electrophoresis only measures protein quantities and cannot detect silent carrier states, compound heterozygous conditions, or rare variants that co-migrate with normal hemoglobin fractions on gel-based assays.
Q2: My partner and I are both asymptomatic — why would we need this before marriage in the UAE?
Asymptomatic sickle cell trait carriers possess one normal HBB allele and one mutated allele, meaning they are clinically silent but have a 25% risk of having a child with full sickle cell disease if both partners carry the trait, which is precisely why the 2026 UAE Premarital Screening Program mandates hemoglobinopathy genetic testing to empower couples with actionable reproductive risk information, carrier detection, and access to prenatal diagnostic options before conception or during early pregnancy.
س3: كم يستغرق وقت ظهور نتائج تحليل طفرة فقر الدم المنجلي، وهل يمكنني الحصول على استشارة طبية بعد النتيجة؟
تظهر نتائج التحليل الجيني الكامل خلال خمسة أيام عمل من تاريخ استلام العينة (تسليم العينة يوم الاثنين قبل الساعة 11 صباحًا، وتصدر النتائج يوم الجمعة)، وتشمل الخدمة استشارة طبية هاتفية لتفسير النتائج مع أحد أطبائنا المتخصصين لضمان فهم كامل للتقرير الجيني وتوجيهك إلى الخطوات السريرية التالية وفقًا لأحدث إرشادات هيئة الصحة بدبي لعام 2026.
ISO 9001:2015 Certified
Certificate: INT/EGQ/2509DA/3139
Facility License: 9834453
VIP Home Collection
Available Daily: 8 AM – 11 PM
ISO Certified Cold-Chain Logistics
Immediate Support
WhatsApp: +971 54 548 8731
Insurance Billing Verification Available
UAE Regulatory Compliance
This service complies with Federal Decree-Law No. 41 of 2024 (Article 87) governing clinical laboratory operations, UAE Communicable Disease Surveillance Law 2026 provisions for minor testing consent, and UAE Personal Data Protection Law (PDPL) for genomic data privacy. All molecular testing is performed in a DHA-licensed facility adhering to ISO 9001:2015 quality management standards.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians